DekaBank Deutsche Girozentrale Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DekaBank Deutsche Girozentrale grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 221,176 shares of the biopharmaceutical company's stock after acquiring an additional 9,969 shares during the period. DekaBank Deutsche Girozentrale owned about 0.20% of Regeneron Pharmaceuticals worth $139,484,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of REGN. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Finally, Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $700.00 to $580.00 in a report on Friday, May 30th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Finally, BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ:REGN traded up $7.98 during midday trading on Friday, hitting $567.74. 844,505 shares of the company's stock were exchanged, compared to its average volume of 915,680. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a 50 day moving average price of $545.22 and a 200-day moving average price of $620.50. The company has a market cap of $61.29 billion, a PE ratio of 14.45, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.62%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.